Thoughts on Preemption in the Wake of the Levine Decision

32 Pages Posted: 18 Feb 2013

See all articles by Erika Lietzan

Erika Lietzan

University of Missouri School of Law

Sarah E. Pitlyk

Independent

Date Written: 2010

Abstract

This article discusses the prospects for preemption doctrine in the wake of the Supreme Court’s decision in Wyeth v. Levine. Part I describes the Levine decision. Part II examines the majority’s holding as it relates to impossibility preemption and considers the future of the doctrine in failure-to-warn suits after Levine. We argue that the announced standard for impossibility preemption — the clear evidence standard — should be interpreted reasonably and not in a manner that effectively eviscerates the doctrine. We also describe other instances of impossibility in the food and drug regulatory context that were not presented to the Court. Part III considers Levine’s obstacle preemption analysis and its implications for future pharmaceutical tort litigation. We conclude that the future for obstacle preemption is uncertain, unless FDA conducts rulemaking on the issue or the Court reconsiders the substantial evidence that state tort litigation impedes FDA’s proper functioning.

Keywords: preemption, FDA, products liability

Suggested Citation

Lietzan, Erika and Pitlyk, Sarah E., Thoughts on Preemption in the Wake of the Levine Decision (2010). Journal of Health Care Law & Policy, Vol. 13, No. 225, 2010. Available at SSRN: https://ssrn.com/abstract=2220020

Erika Lietzan (Contact Author)

University of Missouri School of Law ( email )

Missouri Avenue & Conley Avenue
Columbia, MO MO 65211
United States

Sarah E. Pitlyk

Independent ( email )

No Address Available

Register to save articles to
your library

Register

Paper statistics

Downloads
19
Abstract Views
374
PlumX Metrics